



## Company Overview

Todos Medical Ltd. is an in-vitro diagnostic company engaged in the development of blood tests for the early detection of a variety of cancers, and also has initiated the development of blood tests for neurodegenerative disorders such as Alzheimer's disease through Breakthrough Diagnostics, Inc., its joint venture with Amaranthus Bioscience Holdings, Inc. Todos has developed two cancer screening tests based on TBIA (Todos Biochemical Infrared Analyses), a method for cancer screening using peripheral blood analysis. The TBIA screening method is based on the cancer's influence on the immune system, which triggers biochemical changes in peripheral blood mononuclear cells and plasma. This proprietary and patented method incorporates biochemistry, physics and signal processing. The company's two cancer screening tests, TM-B1 and TM-B2, have received the CE mark. Todos owns 19.99% of Breakthrough Diagnostics, Inc., a joint venture with Amaranthus Bioscience Holdings, Inc. (OTCPK:AMBS) that is developing the LymPro Test®, a blood test for diagnosing Alzheimer's disease. Todos has exercised its option to acquire Breakthrough, and expects to close on that transaction in the first half of 2020. Todos has also entered into an exclusive option to acquire breast cancer blood testing company Provista Diagnostics, Inc. that is commercializing the Videssa® breast cancer blood test.

## Todos Medical Announces \$4.8 Million in Sales for December 2020, a 50% Month Over Month Increase in Sales from November 2020

Jan 11 2021, 8:30 AM EST

## Todos Medical Announces Agreement to Supply Natural Wellness Clinics with COVID-19 Testing Products to Support Initiatives in the Commonwealth of Kentucky

Dec 23 2020, 7:00 AM EST

## Todos Medical Announces Commercial Launch of Proprietary 3CL Protease Inhibitor Dietary Supplement Tollovid™ at The Alchemist's Kitchen

Dec 7 2020, 7:45 AM EST

## Stock Overview

Symbol	TOMDF
Exchange	OTCQB
Market Cap	13.71m
Last Price	\$0.06
52-Week Range	\$0.02 - \$0.19

01/15/2021 03:59 PM EST

## Investor Relations

Daniel Hirsch  
T: 347-699-0029  
[dan.h@todosmedical.com](mailto:dan.h@todosmedical.com)

## Management Team

### Gerald Commissiong

Chief Executive Officer and Director

### Dr. Jorge Leon, Ph.D.

Consulting Chief Medical and Scientific Officer of Infectious Disease and Oncology

### Rami Zigdon, MBA

Chief Business Officer, Co-founder

### Daniel Hirsch, MPH

Chief Financial Officer and Director

### Dr. Elise Brownell

Vice President of Research & Development

### Marsha Fontanive

Vice President of Sales

### Chris Gross

Vice President of Sales Operations

### Priyanka Misra

Vice President of Corporate Development

### Dr. Joseph Wee

Managing Director, Singapore

## Todos Medical Ltd.

1 Hamada Street  
Rehovot 7670301  
Israel

## Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.

